NASDAQ:PRTO Proteon Therapeutics (PRTO) Stock Price, News & Analysis → The AI stock to buy right now (From StockEarnings) (Ad) Free PRTO Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.85▼$3.0050-Day Range$0.84▼$25.1352-Week Range$0.22▼$3.94Volume113,561 shsAverage Volume1.11 million shsMarket Capitalization$64.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Proteon Therapeutics alerts: Email Address Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About Proteon Therapeutics Stock (NASDAQ:PRTO)Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.Read More Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. PRTO Stock News HeadlinesApril 24, 2024 | investing.comProtara Therapeutics Inc (TARA)February 2, 2024 | macrumors.comiPad ProMay 3, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.November 5, 2023 | morningstar.comEsperion Therapeutics Inc ESPRSeptember 20, 2023 | benzinga.comThe Latest Analyst Ratings for Revance TherapeuticsJune 7, 2023 | finance.yahoo.comENLV - Enlivex Therapeutics Ltd.May 25, 2023 | benzinga.comPrelude Therapeutics Insider Trades Send a SignalMay 23, 2023 | benzinga.comGlobal Protein Therapeutics Market Report 2023: Development of Plasma Derived Therapies Drives GrowthMay 3, 2024 | Stansberry Research (Ad)The Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.April 26, 2023 | benzinga.comRAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingFebruary 22, 2023 | benzinga.comEarly Adopter of Remote Therapeutic Monitoring Achieves Significant Clinical and Financial OutcomesJanuary 22, 2023 | finance.yahoo.comCadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO)January 19, 2023 | wsj.comAdvanced Proteome Therapeutics Announces Its Proposed Plan of ArrangementJanuary 19, 2023 | marketwatch.comPeripheral Arterial Disease (PAD) Therapeutics Market 2023 Size & Segmentation Analysis with Share, Trends till 2028 [ NEW REPORT ]January 3, 2023 | benzinga.comBusiness & Academia Join Forces To Study Magic Mushroom Therapy For IBS PatientsOctober 17, 2022 | msn.comWhat 5 Analyst Ratings Have To Say About PTC TherapeuticsSeptember 22, 2022 | msn.comWhat 6 Analyst Ratings Have To Say About Revance TherapeuticsSeptember 9, 2022 | finance.yahoo.comPropella Therapeutics Announces Presentation of Phase 1/2 Data of PRL-02 for the Treatment of Advanced Prostate Cancer at ESMO Congress 2022June 15, 2022 | finance.yahoo.comProthioneTM Capsules Reduced Time to COVID-19 Clinical Resolution and Decreased Viral Load in Phase II Clinical TrialJune 3, 2022 | thestreet.comBristol-Myers To Buy Turning Point Therapeutics In $4.1 Billion Oncology DealMay 27, 2022 | bizjournals.comFlagship Pioneering launches protein startup with $75MSee More Headlines Receive PRTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Proteon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/31/2019Today5/03/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PRTO CUSIPN/A CIK1359931 Webwww.proteontherapeutics.com Phone781-890-0102FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,730,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-118.68% Debt Debt-to-Equity RatioN/A Current Ratio5.98 Quick Ratio5.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-48.17Miscellaneous Outstanding Shares22,179,000Free FloatN/AMarket Cap$64.10 million OptionableNot Optionable Beta0.60 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Timothy P. Noyes (Age 57)Pres, CEO & Director Mr. George A. Eldridge (Age 56)Sr. VP, CFO, Treasurer & Assistant Sec. Dr. Steven Keith Burke (Age 58)Sr. VP & Chief Medical Officer Mr. Matthew P. Kowalsky (Age 46)VP of Legal & Sec. Mr. Bradley J. Hartman (Age 38)VP of People Key CompetitorsElutiaNASDAQ:ELUTIkena OncologyNASDAQ:IKNAInstil BioNASDAQ:TILPrecision BioSciencesNASDAQ:DTILTurnstone BiologicsNASDAQ:TSBXView All Competitors PRTO Stock Analysis - Frequently Asked Questions How were Proteon Therapeutics' earnings last quarter? Proteon Therapeutics Inc (NASDAQ:PRTO) released its quarterly earnings data on Thursday, October, 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. What other stocks do shareholders of Proteon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Proteon Therapeutics investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Sierra Oncology (SRRA), Agile Therapeutics (AGRX), Biocept (BIOC), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO) and Novavax (NVAX). This page (NASDAQ:PRTO) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldThe AI stock to buy right nowStockEarningsCould Your Accounts Be Frozen?Allegiance GoldHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith$5,000 Gold?Stansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
